Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM518D1 in Advanced Solid Tumors
NCT07019779Phase 2Recruiting
- Sponsor
- Keymed Biosciences
- Start
- Jun 2025
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CM518D1 in solid tumor, sponsored by Keymed Biosciences. Started Jun 2025; status: recruiting.
02
Drugs
CM518D1
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07019779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07019779.